Next week, on May 31 in American and June 1 in Europe, we will be discussing the two major AKI studies looking at the timing of renal replacement therapy:
Look for a formal background post later this week.
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
Next week, on May 31 in American and June 1 in Europe, we will be discussing the two major AKI studies looking at the timing of renal replacement therapy:
AKIKI https://t.co/HbpI0AkhPj
— Graham Abra, MD (@GrahamAbra) May 22, 2016
Vs
ELAINhttps://t.co/RVqRSDPm1c
Fight!
Look for a formal background post later this week.